162 related articles for article (PubMed ID: 34120367)
21. GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens.
Shield PW; Papadimos DJ; Walsh MD
Cancer Cytopathol; 2014 Apr; 122(4):307-12. PubMed ID: 24421220
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical evaluation of GATA3 expression in tumors and normal tissues: a useful immunomarker for breast and urothelial carcinomas.
Liu H; Shi J; Wilkerson ML; Lin F
Am J Clin Pathol; 2012 Jul; 138(1):57-64. PubMed ID: 22706858
[TBL] [Abstract][Full Text] [Related]
23. Characterisation of GATA3 expression in invasive breast cancer: differences in histological subtypes and immunohistochemically defined molecular subtypes.
Shaoxian T; Baohua Y; Xiaoli X; Yufan C; Xiaoyu T; Hongfen L; Rui B; Xiangjie S; Ruohong S; Wentao Y
J Clin Pathol; 2017 Nov; 70(11):926-934. PubMed ID: 28428285
[TBL] [Abstract][Full Text] [Related]
24. GATA3 Is a Sensitive and Specific Marker of Benign and Malignant Mesonephric Lesions in the Lower Female Genital Tract.
Howitt BE; Emori MM; Drapkin R; Gaspar C; Barletta JA; Nucci MR; McCluggage WG; Oliva E; Hirsch MS
Am J Surg Pathol; 2015 Oct; 39(10):1411-9. PubMed ID: 26135559
[TBL] [Abstract][Full Text] [Related]
25. Utility of GATA3 immunohistochemistry for diagnosis of metastatic breast carcinoma in cytology specimens.
Braxton DR; Cohen C; Siddiqui MT
Diagn Cytopathol; 2015 Apr; 43(4):271-7. PubMed ID: 25088841
[TBL] [Abstract][Full Text] [Related]
26. Markers of metastatic carcinoma of breast origin.
Gown AM; Fulton RS; Kandalaft PL
Histopathology; 2016 Jan; 68(1):86-95. PubMed ID: 26768031
[TBL] [Abstract][Full Text] [Related]
27. TRPS1 outperforms GATA3 in pleural effusions with metastatic breast carcinoma versus mesothelioma.
Baban F; Koepplin JW; Ahmad M; Clarke-Brodber AL; Bois MC; Hartley CP; Sturgis CD
Diagn Cytopathol; 2023 Aug; 51(8):488-492. PubMed ID: 37096814
[TBL] [Abstract][Full Text] [Related]
28. Differentiating breast carcinoma with signet ring features from gastrointestinal signet ring carcinoma: assessment of immunohistochemical markers.
Hui Y; Wang Y; Nam G; Fanion J; Sturtevant A; Lombardo KA; Resnick MB
Hum Pathol; 2018 Jul; 77():11-19. PubMed ID: 29317235
[TBL] [Abstract][Full Text] [Related]
29. The diagnostic utility of trichorhinophalangeal syndrome type 1 immunohistochemistry for metastatic breast carcinoma in effusion cytology specimens.
Chen CJ; Hang JF; Chen YA; Lin SJ; Chiu HM; Hsu CY; Lai CR; Yang CS
Cancer Cytopathol; 2023 Apr; 131(4):226-233. PubMed ID: 36399408
[TBL] [Abstract][Full Text] [Related]
30. GATA3 is a sensitive marker for primary genital extramammary paget disease: an immunohistochemical study of 72 cases with comparison to gross cystic disease fluid protein 15.
Zhao M; Zhou L; Sun L; Song Y; Guo Y; Zhang X; Zhao F; Wang P; Yue J; Niu D; Li Z; Huang X; Kang Q; Jia L; Lai J; Cao D
Diagn Pathol; 2017 Jul; 12(1):51. PubMed ID: 28693610
[TBL] [Abstract][Full Text] [Related]
31. GATA binding protein 3 (GATA3) as a marker for metaplastic spindle cell carcinoma of the breast.
Jin C; Hacking S; Sajjan S; Kamanda S; Bhuiya T; Nasim M
Pathol Res Pract; 2021 May; 221():153413. PubMed ID: 33770555
[TBL] [Abstract][Full Text] [Related]
32. GATA3 expression in advanced breast cancer: prognostic value and organ-specific relapse.
McCleskey BC; Penedo TL; Zhang K; Hameed O; Siegal GP; Wei S
Am J Clin Pathol; 2015 Nov; 144(5):756-63. PubMed ID: 26486740
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical distinction of primary sweat gland carcinoma and metastatic breast carcinoma: can it always be accomplished reliably?
Mentrikoski MJ; Wick MR
Am J Clin Pathol; 2015 Mar; 143(3):430-6. PubMed ID: 25696802
[TBL] [Abstract][Full Text] [Related]
34. The role of GATA3 in breast carcinomas: a review.
Asch-Kendrick R; Cimino-Mathews A
Hum Pathol; 2016 Feb; 48():37-47. PubMed ID: 26772397
[TBL] [Abstract][Full Text] [Related]
35. GATA3 expression and its relationship with clinicopathological parameters in invasive breast carcinomas.
Cakir A; Isik Gonul I; Ekinci O; Cetin B; Benekli M; Uluoglu O
Pathol Res Pract; 2017 Mar; 213(3):227-234. PubMed ID: 28215639
[TBL] [Abstract][Full Text] [Related]
36. The Utility of GATA3 in the Diagnosis of Urothelial Carcinomas With Variant Morphologic Patterns.
Verduin L; Mentrikoski MJ; Heitz CT; Wick MR
Appl Immunohistochem Mol Morphol; 2016 Aug; 24(7):509-13. PubMed ID: 26317312
[TBL] [Abstract][Full Text] [Related]
37. A combination of GATA3 and SOX10 is useful for the diagnosis of metastatic triple-negative breast cancer.
Tozbikian GH; Zynger DL
Hum Pathol; 2019 Mar; 85():221-227. PubMed ID: 30468800
[TBL] [Abstract][Full Text] [Related]
38. GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors.
Miettinen M; McCue PA; Sarlomo-Rikala M; Rys J; Czapiewski P; Wazny K; Langfort R; Waloszczyk P; Biernat W; Lasota J; Wang Z
Am J Surg Pathol; 2014 Jan; 38(1):13-22. PubMed ID: 24145643
[TBL] [Abstract][Full Text] [Related]
39. GATA3 staining in primary cutaneous apocrine cribriform carcinoma: Usefulness to differentiate it from breast cancer metastasis.
Llamas-Velasco M; Pérez-Gónzalez YC; Daudén E; Rütten A
J Cutan Pathol; 2018 May; 45(5):348-351. PubMed ID: 29431200
[TBL] [Abstract][Full Text] [Related]
40. Combined use of SOX10 and GATA3 in mammary carcinoma.
Qazi MS; McGregor SM
Pathol Res Pract; 2020 Feb; 216(2):152801. PubMed ID: 31924335
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
